X
Kiadis sheds half its staff as lead cell therapy bombs
https://pharmaphorum.com/news/kiadis-sheds-half-its-staff-as-lead-cell-therapy-bombs/
graft versus host disease
Janssen/AbbVie drug approved in graft-versus-host disease
First use for Imbruvica outside blood cancer.
Imbruvica granted fourth Breakthrough status
The drug is also granted Orphan Drug Designation by the FDA.